HIV Drug Resistance in Newly Diagnosed Young Children in the Western Cape, South Africa.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
23 Jul 2024
23 Jul 2024
Historique:
medline:
30
7
2024
pubmed:
30
7
2024
entrez:
30
7
2024
Statut:
aheadofprint
Résumé
Pretreatment of HIV drug resistance among children living with HIV (CLHIV) can compromise antiretroviral therapy (ART) effectiveness. Resistance may be transmitted directly from mothers or acquired following exposure to antiretrovirals consumed through breastfeeding or administered as prophylaxis. We performed resistance testing in children aged <3 years, newly diagnosed with HIV in Western Cape, South Africa (2021-2022), who either (1) acquired HIV via possible breastfeeding transmission from mothers who received ART (any regimen) during pregnancy/postpartum and/or (2) were exposed to protease inhibitors or integrase strand transfer inhibitors (INSTIs) in utero. Possible breastfeeding transmission was defined as testing HIV-polymerase chain reaction positive at age >28 days, after previously testing negative. We used surveillance drug-resistance mutation lists to define mutations. We included 135 CLHIV. Most mothers started ART prepregnancy (73%). Overall, 57% (77/135) of children had resistance mutations detected. Nonnucleoside reverse transcriptase inhibitor-associated, nucleoside reverse transcriptase inhibitor-associated, protease inhibitor-associated and INSTI-associated mutations were found in 55% (74/135), 10% (13/135), <1% (1/135) and <1% (1/122) of children tested, respectively. One child with breastfeeding transmission had high-level INSTI resistance detected at HIV diagnosis, aged 18 months (E138K and G118R mutations). Although not clinically relevant, nonnucleoside reverse transcriptase inhibitor-associated mutations were common. Dolutegravir is currently the preferred first-line treatment for adults and CLHIV age ≥4 weeks, and although very low INSTI resistance levels have been observed in adults, limited data exist on genotyping the integrase region in children. Pretreatment INSTI resistance in children is likely to be unusual, but future surveillance, including longitudinal studies with paired mother-child resistance testing, is needed.
Sections du résumé
BACKGROUND
BACKGROUND
Pretreatment of HIV drug resistance among children living with HIV (CLHIV) can compromise antiretroviral therapy (ART) effectiveness. Resistance may be transmitted directly from mothers or acquired following exposure to antiretrovirals consumed through breastfeeding or administered as prophylaxis.
METHODS
METHODS
We performed resistance testing in children aged <3 years, newly diagnosed with HIV in Western Cape, South Africa (2021-2022), who either (1) acquired HIV via possible breastfeeding transmission from mothers who received ART (any regimen) during pregnancy/postpartum and/or (2) were exposed to protease inhibitors or integrase strand transfer inhibitors (INSTIs) in utero. Possible breastfeeding transmission was defined as testing HIV-polymerase chain reaction positive at age >28 days, after previously testing negative. We used surveillance drug-resistance mutation lists to define mutations.
RESULTS
RESULTS
We included 135 CLHIV. Most mothers started ART prepregnancy (73%). Overall, 57% (77/135) of children had resistance mutations detected. Nonnucleoside reverse transcriptase inhibitor-associated, nucleoside reverse transcriptase inhibitor-associated, protease inhibitor-associated and INSTI-associated mutations were found in 55% (74/135), 10% (13/135), <1% (1/135) and <1% (1/122) of children tested, respectively. One child with breastfeeding transmission had high-level INSTI resistance detected at HIV diagnosis, aged 18 months (E138K and G118R mutations).
CONCLUSIONS
CONCLUSIONS
Although not clinically relevant, nonnucleoside reverse transcriptase inhibitor-associated mutations were common. Dolutegravir is currently the preferred first-line treatment for adults and CLHIV age ≥4 weeks, and although very low INSTI resistance levels have been observed in adults, limited data exist on genotyping the integrase region in children. Pretreatment INSTI resistance in children is likely to be unusual, but future surveillance, including longitudinal studies with paired mother-child resistance testing, is needed.
Identifiants
pubmed: 39079031
doi: 10.1097/INF.0000000000004482
pii: 00006454-990000000-00951
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
K.A., E.K. and M.-A.D. received funding from ViiV Healthcare for this project. The Provincial Health Data Centre was supported by grant U01AI069924 from National Institutes of Health (National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development, National Cancer Institute, National Institute on Drug Abuse and National Institute of Mental Health)—Principal Investigator: M. Egger and M.-A.D. E.K., A.B. and M.-A.D. were supported by grant R01HD080465 from National Institutes of Health (National Institute of Child Health and Human Development). The other authors have no conflicts of interest to disclose.
Références
Waitt CJ, Garner P, Bonnett LJ, et al. Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies. J Antimicrob Chemother. 2015;70:1928–1941.
Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med. 2011;8:e1000430–e1000410.
Fogel J, Li Q, Taha TE, et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis. 2011;52:1069–1076.
Boyce CL, Sils T, Ko D, et al. Maternal human immunodeficiency virus (HIV) drug resistance is associated with vertical transmission and is prevalent in infected infants. Clin Infect Dis. 2022;74:2001–2009.
Dickinson L, Walimbwa S, Singh Y, et al.; DolPHIN-1 Study Group. Infant exposure to dolutegravir through placental and breast milk transfer: a population pharmacokinetic analysis of DolPHIN-1. Clin Infect Dis. 2021;73:e1200–e1207.
Western Cape Health Department. The Western Cape consolidated guidelines for HIV treatment: prevention of mother-to-child transmission of HIV (PMTCT), children, adolescents and adults. 2020. Available from: https://www.westerncape.gov.za/assets/departments/health/hiv_guidelines_16012020.pdf. Accessed May 4, 2023.
Van Laethem K, Schrooten Y, Covens K, et al. A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes. J Virol Methods. 2008;153:176–181.
Salimo AT, Ledwaba J, Coovadia A, et al. The use of dried blood spot specimens for HIV-1 drug resistance genotyping in young children initiating antiretroviral therapy. J Virol Methods. 2015;223:30–32.
Stanford University HIV Drug Resistance Database. Calibrated population resistance tool. Available from: https://hivdb.stanford.edu/cpr/. Accessed December 18, 2023.
Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4:e4724.
Tzou PL, Rhee SY, Descamps D, et al.; WHO HIVResNet Working Groups. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance. J Antimicrob Chemother. 2020;75:170–182.
Boulle A, Heekes A, Tiffin N, et al. Data Centre Profile: The Provincial Health Data Centre of the Western Cape Province, South Africa. Int J Popul Data Sci. 2019;4:1143.
Mutemaringa T, Heekes A, Smith M, et al. Record linkage for routinely collected health data in an African health information exchange. Int J Popul Data Sci. 2023;8:07.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/baseline-evaluation. Accessed January 25, 2024.
European AIDS Clinical Society (EACS) Guidelines, Version 12.0, October 2023. Available from: https://www.eacsociety.org/guidelines/eacs-guidelines/. Accessed January 25, 2024.
Dorward J, Sookrajh Y, Khubone T, et al. Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study. Lancet HIV. 2023;10:e284–e294.
Western Cape Health Department. The Western Cape consolidated guidelines for HIV treatment: prevention of mother- to- child transmission of HIV (PMTCT), children, adolescents and adults 2015. Available from: https://www.westerncape.gov.za/sites/www.westerncape.gov.za/files/the_western_cape_consolidated_guidelines_for_hiv_treatment_29032016.pdf. Accessed May 4, 2022.
National Department of Health, Republic of South Africa. 2023 ART clinical guidelines for the management of HIV in adults, pregnancy and breastfeeding, adolescents, children, infants and neonates. 2023. Available from: https://sahivsoc.org/Files/National.ART.Clinical.Guideline.2023_04.pdf. Accessed August 18, 2023.
Boerma RS, Sigaloff KCE, Akanmu AS, et al. Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis. J Antimicrob Chemother. 2017;72:365–371.
Inzaule SC, Osi SJ, Akinbiyi G, et al. High prevalence of HIV drug resistance among newly diagnosed infants aged <18 months: results from a nationwide surveillance in Nigeria. J Acquir Immune Defic Syndr. 2018;77:1–7.
Kanthula R, Rossouw TM, Feucht UD, et al. Persistence of HIV drug resistance among South African children given nevirapine to prevent mother-to-child-transmission. AIDS. 2017;31:1143–1148.
Poppe LK, Chunda-Liyoka C, Kwon EH, et al. HIV drug resistance in infants increases with changing prevention of mother-to-child transmission regimens. AIDS. 2017;31:1885–1889.
Yeganeh N, Kerin T, Ank B, et al. Human immunodeficiency virus antiretroviral resistance and transmission in mother-infant pairs enrolled in a large perinatal study. Clin Infect Dis. 2018;66:1770–1777.
Bennett SJ, Chunda-Liyoka C, Poppe LK, et al. High nonnucleoside reverse transcriptase inhibitor resistance levels in HIV-1-infected Zambian mother-infant pairs. AIDS. 2020;34:1833–1842.
Hunt GM, Ledwaba J, Salimo A, et al. Prevalence of HIV-1 drug resistance amongst newly diagnosed HIV-infected infants age 4–8 weeks, enrolled in three nationally representative PMTCT effectiveness surveys, South Africa: 2010, 2011–12 and 2012–13. BMC Infect Dis. 2019;19:787.
Louis FJ, Segaren N, Desinor O, et al. High levels of HIV-1 drug resistance in children who acquired HIV Infection through mother to child transmission in the era of option B+, Haiti, 2013 to 2014. Pediatr Infect Dis J. 2019;38:503–507.
Anderson K, Kalk E, Heekes A, et al. Factors associated with vertical transmission of HIV in the Western Cape, South Africa: a retrospective cohort analysis. J Int AIDS Soc. 6235;27:e2.
Francois K, Onacker JDV, Jordan MR, et al. First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir/lamivudine/dolutegravir use in mothers. AIDS. 2023;37:2097–2099.
O’Kelly B, Murtagh R, Lambert JS. Therapeutic drug monitoring of HIV antiretroviral drugs in pregnancy: a narrative review. Ther Drug Monit. 2020;42:229–244.
World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. 2021. Available from: https://www.who.int/publications/i/item/9789240031593. Accessed May 17, 2023.
World Health Organization. HIV drug resistance report 2021. Available from: https://www.who.int/publications/i/item/9789240038608. Accessed January 25, 2024.
Waitt C, Orrell C, Walimbwa S, et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: a randomised trial (DolPHIN-1 study). PLoS Med. 2019;16:e1002895.